These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30149659)

  • 1. Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice.
    Komorowski M; Tisonczyk J; Kolakowska A; Drozdz R; Kozbor D
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30149659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases.
    Gil M; Seshadri M; Komorowski MP; Abrams SI; Kozbor D
    Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1291-300. PubMed ID: 23509246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
    Gil M; Komorowski MP; Seshadri M; Rokita H; McGray AJ; Opyrchal M; Odunsi KO; Kozbor D
    J Immunol; 2014 Nov; 193(10):5327-37. PubMed ID: 25320277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice.
    Gil M; Bieniasz M; Wierzbicki A; Bambach BJ; Rokita H; Kozbor D
    J Immunol; 2009 Nov; 183(10):6808-18. PubMed ID: 19846865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy.
    Komorowski MP; McGray AR; Kolakowska A; Eng K; Gil M; Opyrchal M; Litwinska B; Nemeth MJ; Odunsi KO; Kozbor D
    Mol Ther Oncolytics; 2016; 3():16034. PubMed ID: 28035333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
    Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
    Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.
    Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T
    Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recruitment of Intratumoral CD103
    Mistarz A; Komorowski MP; Graczyk MA; Gil M; Jiang A; Opyrchal M; Rokita H; Odunsi KO; Kozbor D
    Mol Ther Oncolytics; 2019 Sep; 14():233-245. PubMed ID: 31384667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer.
    Francis L; Guo ZS; Liu Z; Ravindranathan R; Urban JA; Sathaiah M; Magge D; Kalinski P; Bartlett DL
    Oncotarget; 2016 Apr; 7(16):22174-85. PubMed ID: 26956047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
    de Vries CR; Monken CE; Lattime EC
    Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects.
    Fu R; Qi R; Xiong H; Lei X; Jiang Y; He J; Chen F; Zhang L; Qiu D; Chen Y; Nie M; Guo X; Zhu Y; Zhang J; Yue M; Cao J; Wang G; Que Y; Fang M; Wang Y; Chen Y; Cheng T; Ge S; Zhang J; Yuan Q; Zhang T; Xia N
    Signal Transduct Target Ther; 2024 May; 9(1):118. PubMed ID: 38702343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
    Alghamri MS; Banerjee K; Mujeeb AA; Mauser A; Taher A; Thalla R; McClellan BL; Varela ML; Stamatovic SM; Martinez-Revollar G; Andjelkovic AV; Gregory JV; Kadiyala P; Calinescu A; Jiménez JA; Apfelbaum AA; Lawlor ER; Carney S; Comba A; Faisal SM; Barissi M; Edwards MB; Appelman H; Sun Y; Gan J; Ackermann R; Schwendeman A; Candolfi M; Olin MR; Lahann J; Lowenstein PR; Castro MG
    ACS Nano; 2022 Jun; 16(6):8729-8750. PubMed ID: 35616289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
    Ino Y; Saeki Y; Fukuhara H; Todo T
    Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
    Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
    Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.